Changes in renal function following nedaplatin‑containing chemotherapy in patients with urothelial carcinoma unfit for cisplatin

Nagasawa,Masayuki; Kageyama,Susumu; Yoshida,Tetsuya; Okinaka,Yuki; Kubota,Shigehisa; Wada,Akinori; Kobayashi,Kenichi; Tomita,Keiji; Murai,Ryosuke; Tsuru,Teruhiko; Johnin,Kazuyoshi; Narita,Mitsuhiro; Kawauchi,Akihiro

doi:10.3892/ol.2018.9859

Changes in renal function following nedaplatin‑containing chemotherapy in patients with urothelial carcinoma unfit for cisplatin

Authors:
- Masayuki Nagasawa
- Susumu Kageyama
- Tetsuya Yoshida
- Yuki Okinaka
- Shigehisa Kubota
- Akinori Wada
- Kenichi Kobayashi
- Keiji Tomita
- Ryosuke Murai
- Teruhiko Tsuru
- Kazuyoshi Johnin
- Mitsuhiro Narita
- Akihiro Kawauchi
View Affiliations

Affiliations: Department of Urology, Shiga University of Medical Science, Otsu, Shiga 520‑2192, Japan
Published online on: December 20, 2018 https://doi.org/10.3892/ol.2018.9859
Pages: 2551-2556

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study evaluated the impact of nedaplatin‑containing chemotherapy on renal function in 35 patients with urothelial carcinoma (UC) between 2001 and 2014 who were unfit for cisplatin treatment. As comparative controls, the present study also examined 35 patients with the same disease who underwent cisplatin‑containing chemotherapy during the same period. The changes in the estimated glomerular filtration rate (eGFR) prior to and following the administration of nedaplatin during each cycle of chemotherapy was investigated. The present study also reported the overall response rates and adverse events in each group. A total of 31 cycles of the gemcitabine/nedaplatin regimen and 66 cycles of the methotrexate/epirubicin/nedaplatin regimen were administered. In the nedaplatin group, the mean eGFRs prior to and following chemotherapy were 45.4 and 47.8 ml/min/1.73 m2, respectively. The eGFR of the post‑chemotherapy group was significantly increased (P<0.001). On the other hand, in the cisplatin group, the eGFR following chemotherapy was significantly lower than the rate prior to chemotherapy (P<0.001). The overall response rates were 30.4 and 66.7% in the nedaplatin and cisplatin groups, respectively. In the two groups, myelosuppression was the most common side effect, but the occurrence rates in both groups were similar, and these adverse events were manageable. With regard to nephrotoxicity, nedaplatin‑containing chemotherapy for cisplatin‑unfit patients with UC is a safe treatment modality.

View Figures

View References

1	De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Gil T, Marreaud S, Daugaard G, Skoneczna I, et al: Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 30:191–199. 2012. View Article : Google Scholar : PubMed/NCBI
2	Dash A, Galsky MD, Vickers AJ, Serio AM, Koppie TM, Dalbagni G and Bochner BH: Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 107:506–513. 2006. View Article : Google Scholar : PubMed/NCBI
3	Kaag MG, O'Malley RL, O'Malley P, Godoy G, Chen M, Smaldone MC, Hrebinko RL, Raman JD, Bochner B, Dalbagni G, et al: Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol. 58:581–587. 2010. View Article : Google Scholar : PubMed/NCBI
4	Galsky MD, Chen GJ, Oh WK, Bellmunt J, Roth BJ, Petrioli R, Dogliotti L, Dreicer R and Sonpavde G: Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol. 23:406–410. 2012. View Article : Google Scholar : PubMed/NCBI
5	Shimada M, Itamochi H and Kigawa J: Nedaplatin: A cisplatin derivative in cancer chemotherapy. Cancer Manag Res. 5:67–76. 2013. View Article : Google Scholar : PubMed/NCBI
6	Akaza H, Togashi M, Nishio Y, Miki T, Kotake T, Matsumura Y, Yoshida O and Aso Y: Phase II study of cis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. 254-S urological cancer study group. Cancer Chemother Pharmacol. 31:187–192. 1992. View Article : Google Scholar : PubMed/NCBI
7	Kuroda M, Kotake T, Akaza H, Hinotsu S and Kakizoe T: Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: A prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese urothelial cancer research group. Jpn J Clin Oncol. 28:497–501. 1998. View Article : Google Scholar : PubMed/NCBI
8	von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 18:3068–3077. 2000. View Article : Google Scholar : PubMed/NCBI
9	Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H and Hishida A; Collaborators developing the Japanese equation for estimated GFR: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 53:982–992. 2009. View Article : Google Scholar : PubMed/NCBI
10	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
11	Alfred Witjes J, Lebret T, Compérat EM, Cowan NC, De Santis M, Bruins HM, Hernández V, Espinós EL, Dunn J, Rouanne M, et al: Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 71:462–475. 2017. View Article : Google Scholar : PubMed/NCBI
12	Shinohara N, Harabayashi T, Suzuki S, Nagao K, Seki H, Murakumo M, Mitsuhashi K, Demura T, Nagamori S, Matsuyama H, et al: Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy. Cancer Chemother Pharmacol. 58:402–407. 2006. View Article : Google Scholar : PubMed/NCBI
13	Kitamura H, Taguchi K, Kunishima Y, Yanase M, Takahashi A, Shigyo M, Tanaka T, Mutoh M, Fukuta F, Masumori N and Tsukamoto T: Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: A phase II study of the SUOC group. Cancer Sci. 102:1171–1175. 2011. View Article : Google Scholar : PubMed/NCBI
14	Umemoto S, Miyoshi Y, Nakaigawa N, Makiyama K, Ogawa T, Uemura H, Yao M and Kubota Y: A pilot study of combination chemotherapy of gemcitabine and nedaplatin for urological cancer. Jpn J Clin Urol. 61:903–908. 2007.
15	Matsumoto M, Takeda Y, Maki H, Hojo K, Wada T, Nishitani Y, Maekawa R and Yoshioka T: Preclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer. Jpn J Cancer Res. 92:51–58. 2001. View Article : Google Scholar : PubMed/NCBI
16	Tian Y, Liu Q and Wu K, Chu Q, Chen Y and Wu K: Meta-analysis comparing the efficacy of nedaplatin-based regimens between squamous cell and non-squamous cell lung cancers. Oncotarget. 8:62330–62338. 2017. View Article : Google Scholar : PubMed/NCBI